OLPRUVA™ (sodium phenylbutyrate) for Oral Suspension

The U.S. Food and Drug Administration (FDA) has approved OLPRUVA™ (sodium phenylbutyrate) for oral suspension in the U.S. More information is available here:

Press Release: Acer Therapeutics and Relief Therapeutics Announce U.S. FDA Approval of OLPRUVA™ for Patients with Urea Cycle Disorders

Full U.S. Prescribing Information

Product Website